Publications by authors named "Abdel-Wahab N"

Background: The impact of steroid-sparing immunosuppressive agents (SSIAs) for immune-related adverse events (irAEs) on tumor outcome is not well-known. This systematic review evaluates tumor outcomes for corticosteroid (CS) monotherapy versus CS with SSIA (CS-SSIA) for irAE treatment with a focus on melanoma.

Methods: Search was conducted through 1/5/23 using PubMed, Embase, Cochrane CENTRAL, and Web of Science.

View Article and Find Full Text PDF

We present an analytical solution for a quantum system characterized by a double five-level atom interacting with an intensity-dependent coupling regime, influenced by a nonlinear Kerr-like medium. We also derive the constants of motion through Heisenberg's equations. Furthermore, the dynamical evolution of the entanglement and quantum coherence between the atom and the field is discussed using linear entropy and -norm of coherence.

View Article and Find Full Text PDF

Gaucher's disease (GD) is a lysosomal storage disorder characterized by the storage of glucosylceramide in macrophages ("Gaucher cells"), mainly in the reticuloendothelial system. GD type 1 (GD1) is the most common phenotype that usually manifests with hepatosplenomegaly, cytopenias, and bone involvement. Skeletal manifestations are the most debilitating characteristic and result in significant morbidities.

View Article and Find Full Text PDF

Background: Cancer patients with autoimmune disease have been excluded from randomized trials of immune checkpoint blockers (ICBs). We conducted a systematic review of observational studies and uncontrolled trials including cancer patients with pre-existing autoimmune disease who received ICBs.

Methods: We searched 5 electronic databases through November 2023.

View Article and Find Full Text PDF

Background: Despite a higher risk of classical Hodgkin lymphoma (cHL) in people with HIV and the demonstrated safety and efficacy of PD-1 blockade in cHL, there are limited data on the use of these agents in HIV-associated cHL (HIV-cHL).

Patients/methods: We retrospectively identified patients with HIV-cHL from the "Cancer Therapy using Checkpoint inhibitors in People with HIV-International (CATCH-IT)" database who received nivolumab or pembrolizumab, alone or in combination with other agents, and reviewed records for demographics, disease characteristics, immune-mediated adverse events (imAEs), and treatment outcomes. Changes in CD4 T-cell counts with treatment were measured via Wilcoxon signed-rank tests.

View Article and Find Full Text PDF

Background: Primary cardiac soft tissue sarcomas (CSTS) affect young adults, with dismal outcomes.

Objectives: The aim of this study was to investigate the clinical outcomes of patients with CSTS receiving immune checkpoint inhibitors (ICIs).

Methods: A retrospective, multi-institutional cohort study was conducted among patients with CSTS between 2015 and 2022.

View Article and Find Full Text PDF

Introduction: The advent of immune checkpoint inhibitors (ICIs) in cancer treatment has marked a transformative era, albeit tempered by immune-related adverse events (irAEs), including those impacting the musculoskeletal system. The lack of precise epidemiologic data on rheumatic irAEs is attributed to factors such as potential underrecognition, underreporting in clinical trials, and the tendency to overlook manifestations without immediate life-threatening implications, further complicating the determination of accurate incidence rates, while the complete understanding of the mechanisms driving rheumatic irAEs remains elusive.

Areas Covered: This literature review comprehensively examines rheumatic irAEs in cancer patients undergoing ICI therapy, encompassing epidemiology, risk factors, mechanisms, clinical manifestations, and current management guidance for prevalent conditions such as inflammatory arthritis, polymyalgia rheumatica, and myositis.

View Article and Find Full Text PDF

Background: Gastric ulcers represent a worldwide health problem, characterized by erosions that affect the mucous membrane of the stomach and may even reach the muscular layer, leading to serious complications. Numerous natural products have been assessed as anti-ulcerogenic agents, and have been considered as new approaches for treatment or prevention of gastric ulcers. The present research investigated the preventive benefits of Apium graveolens L.

View Article and Find Full Text PDF
Article Synopsis
  • Breast cancer is a major health concern, often resistant to treatment and associated with severe side effects from chemotherapy, highlighting the need for safer and more effective therapies.
  • Deferasirox (DFX), an FDA-approved oral iron-chelating drug, has shown promise in combating breast cancer but suffers from poor water solubility.
  • The study developed DFX-loaded lipid nanocapsules (DFX-LNCs), which exhibited significantly greater cytotoxicity and anti-cancer effects in a mouse model compared to free DFX, along with improved apoptosis and antioxidant properties.
View Article and Find Full Text PDF

Unlabelled: The roles of preexisting auto-reactive antibodies in immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy are not well defined. Here, we analyzed plasma samples longitudinally collected at predefined time points and at the time of irAEs from 58 patients with immunotherapy naïve metastatic non-small cell lung cancer treated on clinical protocol with ipilimumab and nivolumab. We used a proteomic microarray system capable of assaying antibody reactivity for IgG and IgM fractions against 120 antigens for systemically evaluating the correlations between auto-reactive antibodies and certain organ-specific irAEs.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with preexisting autoimmune diseases (pAIDs) are often excluded from clinical trials of immune checkpoint inhibitors (ICIs) due to concerns about exacerbating their conditions.
  • This study compared the safety of ICI combinations versus monotherapy in cancer patients with pAIDs, focusing on immune-related adverse events (irAEs) and treatment outcomes like progression-free survival (PFS).
  • Results indicated that while ICI combination therapy had a higher incidence of any-grade irAEs compared to monotherapy, overall, the toxicity profile was manageable, and no treatment-related deaths occurred, suggesting that the combination therapy could be safe for these patients.
View Article and Find Full Text PDF

Immune-related adverse events (irAEs) challenge the use of immune checkpoint inhibitors (ICIs). We performed a retrospective study to evaluate response to infliximab for immune-related adverse event management, and infliximab's effect on progression-free survival (PFS) and overall survival (OS) with a focus on melanoma and genitourinary cancers. We retrospectively reviewed records of all cancer patients exposed to infliximab after immune checkpoint inhibitor (ICI) treatment from 2004 to 2021 at the MD Anderson Cancer Center.

View Article and Find Full Text PDF

Background: Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors.

Methods: This retrospective study included patients with locally advanced or metastatic penile squamous cell carcinoma receiving immune checkpoint inhibitors between 2015 and 2022 across 24 centers in the United States, Europe, and Asia.

View Article and Find Full Text PDF

Background: Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness of anti-interleukin-6 receptor (anti-IL-6R) as therapy for irAEs.

Methods: We performed a retrospective multicenter study evaluating patients diagnosed with de novo irAEs or flare of pre-existing autoimmune disease following ICI and were treated with anti-IL-6R.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the use of immune checkpoint inhibitors (ICIs) in people living with HIV (PWH) who also have cancer, highlighting their historical exclusion from trials compared to those without HIV.
  • A retrospective analysis of 390 PWH treated with anti-PD-1 or anti-PD-L1 therapies shows a diversity of cancers, with a notable response rate and low toxicity profile in this population.
  • The findings suggest that the safety and effectiveness of ICIs are comparable between PWH and those without HIV, indicating that PWH can benefit from these cancer treatments without increased adverse effects.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to compare the safety and efficacy of biologic DMARDs, specifically TNFi and IL6Ri, with conventional DMARD methotrexate (MTX) in patients with inflammatory arthritis linked to immune checkpoint inhibitors (ICI-IA).
  • It included 147 patients and found that TNFi led to quicker cancer progression and faster arthritis control compared to MTX, while results for IL6Ri were less definitive.
  • The conclusion suggests that while biologic DMARDs may provide faster relief from arthritis symptoms, they could also be linked to quicker cancer progression compared to traditional MTX treatment.
View Article and Find Full Text PDF

Background: Immune-related adverse events are a management challenge in patients receiving immune checkpoint inhibitors (ICIs). The most common renal immune-related adverse event, acute interstitial nephritis (AIN), is associated with patient morbidity and mortality. AIN, characterized by infiltration of renal tissue with immune cells, may be analogous to kidney transplant rejection.

View Article and Find Full Text PDF

Objectives: Imaging appearances of immune checkpoint inhibitor-related nephritis have not yet been described. The primary objective of this study is to describe the appearances of immunotherapy-related nephritis on computerized tomography (CT) and positron emission tomography (PET). The secondary objectives are to investigate the association of radiologic features with clinical outcomes.

View Article and Find Full Text PDF

Objectives: We aimed to compare the effects of different aerobic exercise training (ET) programs on respiratory performance, exercise capacity, and quality of life in fibrosing interstitial lung diseases (f-ILD).

Methods: A case-control study where 31 patients with f-ILD diagnosis based on chest high-resolution computed tomography were recruited from Main Alexandria University hospital-Egypt. Ten patients were randomly assigned for only lower limbs (LL) endurance training program, and 10 patients for upper limbs, lower limbs, and breathing exercises (ULB) program for consecutive 18 sessions (3 sessions/week for 6 consecutive weeks).

View Article and Find Full Text PDF

Diabetes mellitus (DM) is a complicated condition that is accompanied by a plethora of metabolic symptoms, including disturbed serum glucose and lipid profiles. Several herbs are reputed as traditional medicine to improve DM. The current study was designed to explore the chemical composition and possible ameliorative effects of on blood glucose and lipid profile in high-fat diet/streptozotocin-induced diabetic rats and in 3T3-L1 cell lines as a first report of its bioactivity.

View Article and Find Full Text PDF

Immune checkpoint blockade (ICB) therapy frequently induces immune-related adverse events. To elucidate the underlying immunobiology, we performed a deep immune analysis of intestinal, colitis, and tumor tissue from ICB-treated patients with parallel studies in preclinical models. Expression of interleukin-6 (IL-6), neutrophil, and chemotactic markers was higher in colitis than in normal intestinal tissue; T helper 17 (Th17) cells were more prevalent in immune-related enterocolitis (irEC) than T helper 1 (Th1).

View Article and Find Full Text PDF

The genus is widely distributed in terrestrial and marine environments. In the marine environment, several species have proved their potential to produce a plethora of secondary metabolites including polyketides, sterols, fatty acids, peptides, alkaloids, terpenoids and miscellaneous compounds, displaying a variety of pharmacological activities such as antimicrobial, cytotoxicity, anti-inflammatory and antioxidant activity. From the beginning of 2015 until December 2020, about 361 secondary metabolites were identified from different marine species.

View Article and Find Full Text PDF

Immune checkpoint inhibitors are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Management of arthritis-irAE is challenging because immunomodulatory therapy for arthritis should not impede antitumor immunity. Understanding of the mechanisms of arthritis-irAE is critical to overcome this challenge, but the pathophysiology remains unknown.

View Article and Find Full Text PDF